Leerink Partnrs Weighs in on Beta Bionics FY2024 Earnings

Beta Bionics, Inc. (NASDAQ:BBNX) – Investment analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Beta Bionics in a research report issued on Monday, February 24th. Leerink Partnrs analyst M. Kratky forecasts that the company will post earnings of ($1.66) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.95) EPS.

BBNX has been the topic of a number of other reports. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a report on Thursday, February 20th. Lake Street Capital started coverage on Beta Bionics in a research report on Monday. They set a “buy” rating and a $30.00 price objective for the company. LADENBURG THALM/SH SH began coverage on Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 target price on the stock. Stifel Nicolaus started coverage on Beta Bionics in a report on Monday. They set a “buy” rating and a $25.00 price target for the company. Finally, Leerink Partners started coverage on Beta Bionics in a report on Monday. They set an “outperform” rating and a $28.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Stock Performance

Beta Bionics stock opened at $19.17 on Wednesday. Beta Bionics has a 1 year low of $19.08 and a 1 year high of $24.50.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger bought 33,350 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the acquisition, the insider now owns 59,019 shares in the company, valued at $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.